

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-102024-0001165

Date: 19/11/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib
- Axinitib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Response

<p>1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):</p> <ul style="list-style-type: none">Avelumab + AxitinibAxinitibCabozantinibEverolimusLenvatinib + EverolimusLenvatinib + PembrolizumabNivolumab monotherapyNivolumab + CabozantinibNivolumab + IpilimumabPazopanibPembrolizumab monotherapyPembrolizumab + AxitinibRadiotherapy onlySunitinibTemsirolimusTivozanibOther active systemic anti-cancer therapyPalliative care only	<table><tr><td>Avelumab + Axitinib</td><td>0</td></tr><tr><td>Axinitib</td><td>< 5</td></tr><tr><td>Cabozantinib</td><td>7</td></tr><tr><td>Everolimus</td><td>< 5</td></tr><tr><td>Lenvatinib + Everolimus</td><td>0</td></tr><tr><td>Lenvatinib + Pembrolizumab</td><td>6</td></tr><tr><td>Nivolumab monotherapy</td><td>< 5</td></tr><tr><td>Nivolumab + Cabozantinib</td><td>< 5</td></tr><tr><td>Nivolumab + Ipilimumab</td><td>0</td></tr><tr><td>Pazopanib</td><td>0</td></tr><tr><td>Pembrolizumab monotherapy</td><td>5</td></tr><tr><td>Pembrolizumab + Axitinib</td><td>0</td></tr><tr><td>Radiotherapy only</td><td>Unknown not recorded in CEPMA System.</td></tr><tr><td>Sunitinib</td><td>5</td></tr><tr><td>Temsirolimus</td><td>0</td></tr><tr><td>Tivozanib</td><td>< 5</td></tr><tr><td>Other active systemic anti-cancer therapy</td><td></td></tr><tr><td>Palliative Care Only</td><td>Unknown not recorded in CEPMA System.</td></tr></table> <p>Please note as per NHS As per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the persons involved and cause distress to Families or Friends. The number of patients treated in the last 3 months with the following agents is less than 5, so Exemption Section 40(2) of the Freedom of Information Act is applied.</p>	Avelumab + Axitinib	0	Axinitib	< 5	Cabozantinib	7	Everolimus	< 5	Lenvatinib + Everolimus	0	Lenvatinib + Pembrolizumab	6	Nivolumab monotherapy	< 5	Nivolumab + Cabozantinib	< 5	Nivolumab + Ipilimumab	0	Pazopanib	0	Pembrolizumab monotherapy	5	Pembrolizumab + Axitinib	0	Radiotherapy only	Unknown not recorded in CEPMA System.	Sunitinib	5	Temsirolimus	0	Tivozanib	< 5	Other active systemic anti-cancer therapy		Palliative Care Only	Unknown not recorded in CEPMA System.
Avelumab + Axitinib	0																																				
Axinitib	< 5																																				
Cabozantinib	7																																				
Everolimus	< 5																																				
Lenvatinib + Everolimus	0																																				
Lenvatinib + Pembrolizumab	6																																				
Nivolumab monotherapy	< 5																																				
Nivolumab + Cabozantinib	< 5																																				
Nivolumab + Ipilimumab	0																																				
Pazopanib	0																																				
Pembrolizumab monotherapy	5																																				
Pembrolizumab + Axitinib	0																																				
Radiotherapy only	Unknown not recorded in CEPMA System.																																				
Sunitinib	5																																				
Temsirolimus	0																																				
Tivozanib	< 5																																				
Other active systemic anti-cancer therapy																																					
Palliative Care Only	Unknown not recorded in CEPMA System.																																				
<p>Q2. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?</p>	<p>Based on the codes provided we have had 14 patients undergo full/partial nephrectomy.</p>																																				
<p>Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?</p> <ul style="list-style-type: none">Nivolumab (monotherapy)	<table><tr><td>Nivolumab (monotherapy)</td><td>0</td></tr></table>	Nivolumab (monotherapy)	0																																		
Nivolumab (monotherapy)	0																																				

<ul style="list-style-type: none">Nivolumab + IpilimumabNivolumab + CabozantinibAvelumab + Axitinib <p>*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.</p>	Nivolumab + Ipilimumab	0
	Nivolumab + Cabozantinib	< 5
	Avelumab + Axitinib	0
	<p>Please note as per NHS As per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the persons involved and cause distress to Families or Friends. The number of patients treated in the last 3 months with the following agents is less than 5, so Exemption Section 40(2) of the Freedom of Information Act is applied.</p>	
Q4. Does you Trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?	No	

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell’s Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**